By Fineline Cube Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced that it has submitted a New Drug Application (NDA) to China’s National Medical Products Administration (NMPA) for opamtistomig (LBL‑024) as a monotherapy for advanced, previously treated extrapulmonary neuroendocrine carcinoma (EP‑NEC) — a filing that could produce the first approved drug for this rare, aggressive cancer.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Submission Type | New Drug Application (NDA) |
| Product | Opamtistomig (LBL‑024) |
| Regimen | Monotherapy |
| Indication | Advanced, previously treated extrapulmonary neuroendocrine carcinoma (EP‑NEC) |
| Sponsor | Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) |
| Submission Date | 21 Aug 2026 |
Drug Profile & Mechanism
- Molecule: Bispecific antibody targeting PD‑L1 and the costimulatory receptor 4‑1BB
- First-in-Class Status: The world’s first molecule targeting 4‑1BB to reach the single‑arm pivotal clinical trial stage
- Pioneering Potential: Has the potential to become the first approved drug for the treatment of EP‑NEC, a disease with no targeted therapy currently available
Regulatory Designations – Four Major Accolades
| Designation | Agency | Date |
|---|---|---|
| Breakthrough Therapy Designation | NMPA Center for Drug Evaluation (CDE) | October 2024 |
| Orphan Drug Designation | U.S. FDA | November 2024 |
| Fast Track Designation | U.S. FDA | January 2026 |
| Orphan Drug Designation | European Union | January 2026 |
Market Impact & Outlook
- First-to-File in an Empty Category: With no approved therapy for EP‑NEC, an NDA acceptance — and eventual approval — would establish opamtistomig as the sole targeted option in a disease where treatment today relies on chemotherapy with limited durable benefit.
- Novel Immunotherapy Mechanism: As the first 4‑1BB‑targeting molecule to reach pivotal stage globally, opamtistomig validates a costimulatory approach that complements PD‑L1 blockade — with potential applicability well beyond EP‑NEC if the platform proves durable.
- Global Regulatory Momentum: Four premium designations across the NMPA, FDA and EU within roughly 15 months signal alignment among major regulators on the drug’s unmet-need value, supporting potential filings in the U.S. and Europe alongside China.
- Next Milestones: Investors will watch for NDA acceptance by the CDE, the timeline to approval under Breakthrough Therapy pathways, and subsequent U.S./EU regulatory submissions leveraging Fast Track and Orphan Drug status.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory review, approval timelines and commercial potential of opamtistomig (LBL‑024). Actual results may differ due to risks including CDE review outcomes, confirmatory data requirements, and competitive developments in neuroendocrine tumor therapeutics.-Fineline Info & Tech